A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations
M.D. Anderson Cancer Center
Summary
To study the safety and possible side effects of using the imaging agent 4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN) in PET/CT scans for participants with chronic GVHD.
Description
Primary Objective: Determine the spatial and temporal correlation between \[18F\]4FN PET/CT measurements and the clinical manifestations and severity of chronic GVHD. Investigators hypothesize that \[18F\]4FN PET/CT imaging features will anatomically and by intensity (SUV) correlate with concurrent chronic GVHD manifestations. Investigators also hypothesize that PET/CT imaging features will temporally precede chronic GVHD manifestations at target anatomic locations.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria 1. Chronic GVHD involving the joints, defined as any limitation of range of motion measured by Photographic Range Of Motion (PROM). Criteria can be found at (Jagasia, et al. 2015). 2. Able to give written informed consent. 3. ≥18 years of age 4. Creatinine clearance ≥ 30 mL/min/1.73m2 5. Non-joint chronic GVHD diagnostic / distinctive features are allowed. 6. Subjects may be planned to receive a new systemic therapy for chronic GVHD 7. Prior/continuing systemic therapy for chronic GVHD is allowed 8. ECOG performance status ≤2 9. Ability to understand and the willingness t…
Interventions
- Drug[18F]-4FN
Given by IV
- OtherPET-CT
Imaging
Location
- MD Anderson Cancer CenterHouston, Texas